Akcea et Ionis annoncent l’homologation de TEGSEDIMC (inotersen pour injection) au Canada
October 04, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
OTTAWA et BOSTON et CARLSBAD, Californie, 04 oct. 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ : AKCA), une société affiliée d’Ionis Pharmaceuticals, Inc. (NASDAQ : IONS), a annoncé...
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
October 04, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
OTTAWA and BOSTON and CARLSBAD, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx
September 24, 2018 07:00 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
Study demonstrates significant Lp(a) reduction, favorable safety and tolerability profile Largest and longest study of Ionis’ LICA technology Data to be presented as a late-breaking clinical trial...
Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference
August 29, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today announced that management will present a company...
Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA
August 27, 2018 16:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and CARLSBAD, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA) an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea Reports Financial Results and Highlights for Second Quarter 2018
August 06, 2018 16:05 ET
|
Akcea Therapeutics, Inc.
TEGSEDI™ (inotersen) Approved in European Union $382 million to fund the company through key milestones in 2019 Conference Call Webcast Monday, August 6, 4:30 p.m. ET at...
Akcea Announces Publication of Study Results Showing Multiple Benefits of Patient-to-Patient Connectivity in FCS
July 31, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
Results from the first-ever study evaluating quality of life in people with FCS and impact of patient connectivity published in Expert Opinion on Orphan Drugs. Both active and passive connectivity...
Akcea Therapeutics to Hold Second Quarter 2018 Financial Results Webcast
July 23, 2018 16:30 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Monday,...
Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union
July 11, 2018 07:30 ET
|
Akcea Therapeutics, Inc.; Ionis Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea Announces Completion of Landmark Study to Assess Disease Burden in People Living with FCS
June 13, 2018 07:00 ET
|
Akcea Therapeutics, Inc.
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...